PSA CA MARKER ÎN EVOLUȚIA CANCERULUI DE PROSTATÃ

  • Daniela RUSU Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași
  • V. RUSU Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași
  • Irena RAILEANU Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași
  • Cipriana STEFANESCU Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași
Keywords: PSA, PROGRESSION OF PROSTATE CANCER, BIOCHEMICAL RECURRENCE/ RECURRENCE OF TUMORAL MARKERS

Abstract

Monitoring
the evolution of prostate cancer has crucial importance since this tip of neoplasia has a variable
biology, ranging from latent cancers to extremely aggressive tumors. At the moment, PSA
(prostate specific antigen) values point out to either successful or unsuccessful prostate cancer
therapy. Depending on therapeutic strategies, biochemical recurrence (BCR) is differently
defined. After radical prostatectomy, the PSA declines to undetectable levels in 3-4 weeks;
BCR: PSA = 0.2-0.5 ng/mL for a single measurement or two consecutive values which
surpass 0,2-0,4 ng/mL. PSADT < 10 months is a predictor for the progression of the disease.
After external beam therapy, PSA is slowly decreasing reaching up the nadir of 0.2-0.5 ng/mL
in months or years; BCR: PSA = nadir + 2 ng/mL. In the case of brachytherapy, the nadir
is reached in 2-4 years; BCR: nadir + 2 ng/mL. After hormonal therapy, PSA declines in 3-6
months, maintains low values for 18-24 months, then increases, settling for hormone independency.
After chemotherapy, PSA is considered normal at values < 2 ng/mL; the response of
PSA represents a confirmed decreasing from the second test at 4 or more weeks after the initial
decline; the length of the response is the period between first decline with 50 % of PSA to 50
% increase from nadir; the progression of PSA is shown in the increase with 25 % in
comparison to the basic level. In the case of active monitoring, a PSADT < 2 years is an
indication for radical prostatectomy, but there are cancers which can evoluate despite a stable
PSA. The PSA bounce phenomenon and the PSA surge postchimiotherapie syndrome can
complicate the assessment of biochemical recurrence.

Author Biographies

Daniela RUSU, Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași

Doctorand

V. RUSU, Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași

Facultatea de Medicinã
Disciplina de Biofizicã și Fizicã Medicalã - Medicinã Nuclearã

Irena RAILEANU, Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași

Facultatea de Medicinã
Disciplina de Biofizicã și Fizicã Medicalã - Medicinã Nuclearã

Cipriana STEFANESCU, Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași

Facultatea de Medicinã
Disciplina de Biofizicã și Fizicã Medicalã - Medicinã Nuclearã

References

1. Tomlins SA, Chinnaiyan AM. Expression profiling of prostate cancer progression. In: Chung
LWK, Isaacs WB, Simons JW editors. Prostate Cancer – Biology, Genetics and the New
Therapeutics. Totowa, New Jersey: Humana Press, 2007, 139-163.
2. Nielsen ME, Partin A. The impact of definitions of failure on the interpretation of biochemical
recurrence following treatment of clinically localised prostate cancer. Rev Urol 2007; 9 (2): 57-62.
3. Jiménez JA, Li X, Gardner TA, Kao C. Gene therapy for aAdvanced prostate cancer. In: Chung
LWK, Isaacs WB, Simons JW editors. Prostate Cancer – Biology, Genetics and the New
Therapeutics. Totowa, New Jersey: Humana Press, 2007, 139-163.
4. Wilkinson AN, Brundage MD, Siemens R. Approach to primary care follow-up of patients with
prostate cancer. Can Fam Physician 2008; 54: 204-210.
5. Schroeck FR, Aronson WJ, Presti Jr JC et al. Do nomograms predict aggressive recurrence after radical
prostatectomie more accurately than biochemical recurrence alone? BJU Int 2009; 103 (5): 603-608.
6. Suardi N, Porter CR, Reuther AM, Walz J, Kodama K, Gibbons RP. A nomogram predicting
long-term biochemical recurrence after radical prostatectomy. Cancer 2008; 112: 1254-1263.
7. Kelloff GJ, Choyke P, Coffey DS. Challenges in clinical prostate cancer: role of imaging. AJR
2009; 192: 1455-1470.
8. Motet N, Schalken JA, Heidenreich A et al. Highlights on prostate cancer from urological and
oncological congresses in 2007. Eur Urol Suppl 2008; 7: 460-476.
9. Arlen PM, Bianco F, Dahut WL et al. Prostate-specific antigen working group’s guideliness on
PSA doubling time. J Urol 2008; 179 (6): 2181-2186.
10. Fitzpatrick JM, Anderson J, Sternberg CN et al. Optimizing treatment for men with advanced
prostate cancer: Expert recommandations and the multidisciplinary approach. Crit Rev Oncol
Hematol 2008; 68 (S): 9-22.
11. Benchikh El Fegoun A, Villers A, Moreau JL, Richaud P, Rebillard X, Beuzeboc P. PSA et suivi
après traitement du cancer de la prostate. Prog Urol 2008; 18 (3): 137-144.
12. Heidenreich A, Aus G, Bolla M et al. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80.
13. Stock RG, Klein TJ, Cesaretti JA, Stone NN. Prognostic significance of 5-year PSA value for
predicting prostate cancer recurrence after brachypherapy alone and combined with hormonal
therapy and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys 2009; 74 (3): 753-758.
14. Wolf A, Wender RC, Etzioni RB, Thompson IM, D’Amico V, Volk RJ. American Cancer Society
guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010; 60: 70-98.
15. Abrahamsson PA, Tinzl M. Do we need PSA and early detection on prostate cancer? Eur Urol
Suppl 2008; 7: 393-395.
16. Ross AE, Loeb S, Landis P et al. Prostate-specifique antigen kinetics during follow-up are un
unrealiable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010;
28 (17): 2810-2816.
17. Green MG, Hortobagyi GN. Chemoterapy. In: Jasmin C, Capanna R, Coleman RE, Coia LR,
Saillant R editors. Textbook of Bone Metastases. Wiley, 2005, 261-276.
18. Thuret R, Massard C, Gross-Goupil M et al. The postchemotherapie PSA surge syndrome. Ann
Oncol 2008; 19 (7): 1308-1311.
19. Chow E, Moore MJ, Wu J, Warde P, Perez CA. Prostate cancer. In: Jasmin C, Capanna R,
Coleman RE, Coia LR, Saillant R editors. Textbook of Bone Metastases. Wiley, 2005, 483-504.
Published
2019-11-04